SCHEMBL2897159

SCHEMBL2897159

Ic1cccc(-n2nnc(/C=C/c3ccccc3)n2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.39
GRM5 P41594 7/20 0.39
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ADORA1 P30542 1/20 0.35
MEN1 O00255 1/20 0.34
MPO P05164 1/20 0.34
ABCG2 Q9UNQ0 1/20 0.33
FAAH O00519 1/20 0.33
MGLL Q99685 1/20 0.33
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33
TUBA3C P0DPH7 1/20 0.33
TUBA1B P68363 1/20 0.33
TUBA4A P68366 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2897163 1.00 APP (0.39) APPGRM5KMT2AALDH1A1LMNA
SCHEMBL2897293 0.83 GRM5 (0.46) GRM5KMT2AALDH1A1LMNAGAA
SCHEMBL2889795 0.83 GRM5 (0.46) GRM5KMT2AALDH1A1LMNAGAA
SCHEMBL2889796 0.83 GRM5 (0.46) GRM5KMT2AALDH1A1LMNAGAA
SCHEMBL2897290 0.83 GRM5 (0.46) GRM5KMT2AALDH1A1LMNAGAA
SCHEMBL2895890 0.80 GRM5 (0.53) GRM5ALDH1A1MAPTKDM4E
SCHEMBL2895892 0.80 GRM5 (0.53) GRM5ALDH1A1MAPTKDM4E
SCHEMBL2893751 0.80 FAAH (0.40) GRM5MPOFAAHMGLL
SCHEMBL699967 0.69 APP (0.70) APPKMT2AALDH1A1HPGDMEN1
SCHEMBL29446277 0.69 APP (0.70) APPKMT2AALDH1A1HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1716125-B1 TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS ASTRAZENECA AB (SE) 2013-06-19 EP disclosed
US-7691892-B2 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2010-04-06 US disclosed
US-20070197549-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-08-23 US disclosed
EP-1716125-A1 TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS AstraZeneca AB (SE) 2006-11-02 EP disclosed
US-20060004021-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB 2006-01-05 US disclosed
WO-2005080356-A1 TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS ASTRAZENECA AB (SE) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004021-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists GRM1, GRM3, GRM4 APP 1869/4885GRM5 10/4885KMT2A 2233/4885
US-20070197549-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists GRM1, GRM3, GRM4 APP 1923/4885GRM5 10/4885KMT2A 2227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.